Peptide Therapy for Athletes, Older Adults, and TRT Users: A Clinical Guide

What Are Peptide Therapies and Why Do Athletes Use Them?

Peptides are short chains of two or more amino acids that act as signaling molecules, telling cells to repair tissue, release hormones, or modulate inflammation. Athletes use them primarily because certain peptides stimulate the body's own growth hormone (GH) axis or accelerate musculoskeletal healing, offering a recovery edge without exogenously administered human growth hormone itself.

The GH secretagogue class, which includes sermorelin, CJC-1295, ipamorelin, and tesamorelin, works by binding to receptors in the pituitary or hypothalamus and prompting a pulse of GH release. This is mechanistically different from injecting synthetic GH directly. The pulsatile, physiological GH release may reduce the risk of the side-effect profile associated with supraphysiological GH, such as acromegaly or insulin resistance, although long-term safety data in healthy athletes remain limited [1].

A 2019 systematic review published in the Journal of the International Society of Sports Nutrition found that GH secretagogues increased lean body mass and reduced fat mass in adults with GH deficiency, but acknowledged that data in GH-sufficient, recreationally active adults were insufficient to make firm efficacy claims [2]. That gap matters clinically. Patients who are not GH-deficient may see modest rather than dramatic body-composition changes.

Beyond the GH axis, peptides like BPC-157 and TB-500 (thymosin beta-4) are used for their direct tissue-repair properties. BPC-157 has demonstrated tendon and ligament healing in rat models at doses of 10 mcg/kg [3]. Human clinical trial data are sparse, but the mechanistic rationale, angiogenesis promotion and COX-2 pathway modulation, has kept it popular in sports medicine circles.

How Peptides Support Athletic Recovery Specifically

Recovery is where the evidence is most compelling, even if the bulk of it is preclinical. BPC-157 accelerates healing in gastric ulcer, tendon, ligament, and muscle injury models by upregulating growth hormone receptor expression locally [3]. TB-500, a synthetic version of thymosin beta-4, reduces inflammation and promotes actin polymerization, a step required for cell migration during tissue repair.

For endurance athletes, the GH secretagogue CJC-1295 (a GHRH analogue with a drug affinity complex, or DAC, modification) extends the GH pulse duration to 6 to 8 days per injection because it binds albumin, effectively acting as a depot formulation [4]. Stacking CJC-1295 with ipamorelin, a selective ghrelin receptor agonist, produces a stronger, cleaner GH pulse with less cortisol and prolactin elevation than older secretagogues like GHRP-6 [5].

A practical clinical framework for peptide selection in athletes looks like this. First, define the primary goal: body composition, injury recovery, sleep quality, or all three. Second, determine GH status with an IGF-1 serum level. An IGF-1 below 150 ng/mL in a patient over 35 suggests the GH axis may benefit from secretagogue support. Third, screen for contraindications, particularly active malignancy, since GH axis stimulation is contraindicated in cancer. Fourth, choose the secretagogue appropriate to the dosing schedule the patient can realistically maintain.

Patients who train intensely four or more days per week and sleep fewer than 7 hours per night may also benefit from peptide-supported sleep architecture improvement. Ipamorelin in particular produces its GH pulse during slow-wave sleep when dosed 30 minutes before bed, aligning with the body's natural nocturnal GH surge [5].

Peptide Therapy in Postmenopausal Women

Postmenopausal women face a compounding challenge. Estrogen loss accelerates bone resorption, reduces collagen synthesis, and shifts body composition toward central adiposity. GH secretion also declines with age independent of menopause, so women in their 50s and 60s may lose the anabolic signaling from both the estrogen and GH axes simultaneously.

Sermorelin has been used in this population specifically because it stimulates endogenous GH rather than bypassing the pituitary. A 2002 study by Sigalos and Pastuszak, published in Therapeutic Advances in Urology, found that GH-axis peptide therapy improved body composition and quality-of-life markers in adults over 40 with partial GH deficiency [6]. Postmenopausal women in that analysis showed reduced visceral fat and improved lean mass over 6 months of sermorelin therapy.

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults states that "GH replacement in adults with confirmed GH deficiency improves body composition, bone density, lipid profiles, and quality of life" [7]. While postmenopausal women without confirmed GHD occupy a gray zone, physicians routinely apply these principles when IGF-1 is low-normal and symptoms are consistent.

Bone density is a secondary but meaningful concern. BPC-157 has shown osteogenic effects in animal models by stimulating bone morphogenetic protein (BMP) signaling [3]. Its application in postmenopausal women with osteopenia is investigational, but some clinicians include it as an adjunct alongside standard osteoporosis management.

Collagen peptides, distinct from pharmaceutical peptides, also have a modest evidence base in this population. A randomized controlled trial (N=102) published in Nutrients in 2018 found that 5 g/day of specific collagen peptides for 12 months increased bone mineral density in postmenopausal women with osteopenia by 3.1% at the spine compared to placebo (P<0.05) [8].

Peptide Use in Older Adults and Sarcopenia Management

Muscle loss. It accelerates after 50 at roughly 1 to 2% per year, and by age 70 some individuals have lost 30 to 40% of peak muscle mass [9]. This is sarcopenia, and it carries direct consequences for fall risk, metabolic health, and independence.

GH secretagogues have been tested as a sarcopenia intervention. A 12-week, placebo-controlled trial (N=65) published in the Journal of Clinical Endocrinology and Metabolism found that MK-677 (ibutamoren), an oral ghrelin mimetic with secretagogue properties, increased lean body mass by 1.66 kg and IGF-1 by 40% in adults aged 60, 81 (P<0.05 vs. placebo) [10]. Muscle strength, however, did not improve significantly over that short duration, which underscores that body composition gains require concurrent resistance exercise to translate into functional benefit.

Older adults also tolerate certain peptides differently. The GH-associated side effect of fluid retention and carpal tunnel syndrome appears more frequently in older patients because baseline GH sensitivity is higher relative to their low secretory baseline. Starting ipamorelin or sermorelin at 100 mcg per night and titrating based on 4-week IGF-1 testing is a standard clinical approach.

Post-surgical older adults represent a distinct subcategory. BPC-157 has shown accelerated healing of surgically created tendon and ligament injuries in animal models at 10 mcg/kg/day [3]. Clinicians sometimes prescribe BPC-157 in the 200 to 500 mcg/day range in the peri-surgical period for elderly patients undergoing orthopedic procedures, though this remains off-label and lacks randomized controlled trial data in humans. The rationale is the peptide's demonstrated upregulation of GH receptor expression at the injury site, which may compensate for the blunted GH response that characterizes older surgical patients.

Tesamorelin is the one GH secretagogue with an FDA approval, granted in 2010 for HIV-associated lipodystrophy at 2 mg/day subcutaneous [11]. Its effects on visceral fat in that population have been studied in a 26-week trial (N=412) showing a 15.2% reduction in visceral adipose tissue vs. 1.1% with placebo (P<0.001) [12]. Clinicians working with elderly patients with documented visceral adiposity sometimes use tesamorelin off-label, citing this mechanism.

Combining Peptides With TRT

Testosterone replacement therapy restores the androgen axis. Peptide secretagogues restore the GH/IGF-1 axis. These are complementary systems, not redundant ones, which is why combining them is clinically logical for patients with deficiency in both.

Testosterone increases IGF-1 receptor sensitivity in muscle tissue, meaning that even modest rises in IGF-1 from a secretagogue can produce amplified anabolic effects in the presence of TRT [13]. A 2001 landmark study by Bhasin et al. in the New England Journal of Medicine (N=61) showed that testosterone plus GH produced greater gains in lean mass than either agent alone in older men, though the combination also increased adverse events including glucose intolerance [9]. This underscores the need for monitoring fasting glucose and HbA1c in any patient on dual therapy.

The practical protocol most HealthRX physicians use for TRT plus peptide therapy begins with optimizing testosterone first. Serum total testosterone should reach the patient's target range, typically 700 to 900 ng/dL for symptomatic males, before adding a secretagogue. Adding CJC-1295 plus ipamorelin before testosterone is stable can make it harder to attribute side effects and body-composition changes to either agent.

Once TRT is stable, IGF-1 is measured. If IGF-1 is below 150 ng/mL, adding ipamorelin 200 mcg nightly is a reasonable starting point. If IGF-1 is 150 to 200 ng/mL but body composition goals remain unmet, CJC-1295 without DAC (200 mcg) combined with ipamorelin (200 mcg) subcutaneously five nights per week is the standard regimen. IGF-1 is retested at 8 weeks and dose is adjusted to keep IGF-1 in the 200 to 300 ng/mL range, which correlates with the youthful physiological range without supraphysiologic risk.

For men on TRT who also have joint pain from heavy training, adding BPC-157 at 250 mcg subcutaneously per day for a 4 to 8 week cycle targeting the affected area (periarticularly, guided by the prescribing physician) is a common adjunct. The anti-inflammatory mechanism of BPC-157, specifically its modulation of the nitric oxide pathway and promotion of angiogenesis, may accelerate recovery from training-induced micro-trauma [3].

Women on hormone replacement therapy (HRT) who are also training athletically follow a similar logic. Estradiol affects GH pulsatility directly. Oral estradiol, unlike transdermal forms, reduces IGF-1 by approximately 20 to 30% due to first-pass hepatic effects on IGF-1 synthesis [14]. Postmenopausal women on oral estradiol who present with low IGF-1 should be counseled that switching to transdermal estradiol may improve IGF-1 before a peptide secretagogue is added.

Dosing Reference by Patient Category

Dosing is not one-size-fits-all. The table below reflects typical starting ranges used in clinical practice. Individual prescribers may adjust based on IGF-1 response, side-effect profile, and patient goals.

Athlete (aged 25, 45, GH-sufficient, recovery focus) BPC-157: 200 to 500 mcg/day subcutaneous for 4 to 8 weeks. TB-500: 5 mg subcutaneous twice weekly for 4 weeks, then 2 mg weekly for maintenance.

Postmenopausal woman (aged 50, 65, low IGF-1, body composition goal) Sermorelin: 200 to 500 mcg subcutaneous nightly before bed, 5 nights per week. Reassess IGF-1 at 12 weeks.

Older adult (aged 65+, sarcopenia, post-surgical) Ipamorelin: 100 mcg nightly, titrate to 200 mcg at 4 weeks if tolerated. BPC-157: 200 mcg/day for 4 to 6 weeks post-surgery (off-label, physician discretion).

TRT patient seeking body-composition optimization CJC-1295 (no DAC) 200 mcg + ipamorelin 200 mcg, subcutaneous, 5 nights per week. Target IGF-1: 200 to 300 ng/mL.

All subcutaneous injections should use a 29, 31 gauge, 5/16-inch insulin syringe. Injection sites are rotated across the abdomen, thigh, or lateral flank.

Safety, Side Effects, and What to Monitor

No peptide discussed here is without risk. Common side effects of GH secretagogues include water retention (particularly in the first 4 to 6 weeks), tingling in the hands consistent with carpal tunnel syndrome, increased hunger with GHRP-class peptides like GHRP-6, and transient fatigue or headache.

Glucose metabolism deserves careful attention. GH raises fasting blood glucose through hepatic gluconeogenesis. Patients with pre-diabetes (fasting glucose 100 to 125 mg/dL or HbA1c 5.7 to 6.4%) should have fasting glucose checked at baseline and at 8 weeks after starting any GH secretagogue. The MK-677 trial (N=65) cited above found a statistically significant rise in fasting glucose of 0.3 mmol/L at 12 months (P<0.05) [10], which is modest but clinically meaningful in at-risk patients.

BPC-157 and TB-500 have no published human safety trials, which is a meaningful limitation. Their safety profiles in humans are extrapolated almost entirely from rodent studies. Clinicians prescribing these compounds should document informed consent explicitly, noting that human trial data are absent.

The Endocrine Society states that "GH therapy should not be initiated in the presence of active malignancy, diabetic retinopathy, or critical illness" [7]. This applies equally to secretagogues that stimulate endogenous GH. Cancer screening current to guidelines (mammography, colonoscopy, PSA where appropriate) should be confirmed before initiating secretagogue therapy in patients over 50.

Drug interactions are generally limited. BPC-157 appears to modulate the dopaminergic and serotonergic systems in animal models, so co-prescribing with SSRIs, dopamine agonists, or antipsychotics warrants physician caution, though no human pharmacokinetic studies exist to quantify the interaction [3].

Regulatory and Anti-Doping Considerations

Most peptides discussed here, including BPC-157, CJC-1295, ipamorelin, sermorelin, and TB-500, are compounded by 503A or 503B pharmacies and are not FDA-approved for athletic performance or body-composition indications. Tesamorelin (Egrifta) is the only FDA-approved GH secretagogue, and only for HIV lipodystrophy [11].

The World Anti-Doping Agency (WADA) prohibits GH-releasing peptides and secretagogues in competition. Athletes subject to WADA testing who are prescribed these compounds face a positive test result and potential sanctions, regardless of the therapeutic intent. Any competitive athlete considering peptide therapy must confirm their sport's testing rules before starting.

The FDA's 2023 guidance on bulk drug substances listed several peptides, including BPC-157, as not eligible for compounding under Section 503A, which has created access variability depending on state pharmacy regulations [15]. Patients should verify that their compounding pharmacy holds current PCAB accreditation and that the prescribing physician has documented a legitimate medical purpose in the chart.